Last $2.54 USD
Change Today 0.00 / 0.00%
Volume 0.0
CLSN On Other Exchanges
As of 8:10 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

celsion corp (CLSN) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/24/13 - $5.90
52 Week Low
10/15/14 - $2.38
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELSION CORP (CLSN)

celsion corp (CLSN) Related Bloomberg News

View More Bloomberg News

celsion corp (CLSN) Related Businessweek News

No Related Businessweek News Found

celsion corp (CLSN) Details

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; under Phase II clinical trials for recurrent chest wall breast cancer; and in phase II clinical trials for colorectal liver metastasis. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

13 Employees
Last Reported Date: 03/13/14
Founded in 1982

celsion corp (CLSN) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $434.1K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $275.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $328.5K
Compensation as of Fiscal Year 2013.

celsion corp (CLSN) Key Developments

Celsion Corporation Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board

Celsion Corporation announced that the board of directors has appointed Michael H. Tardugno, the company's President and CEO, to the additional position of executive chairman of the board. Mr. Tardugno's appointment is consistent with the Board's previously established succession plan and follows the passing of Max E. Link, Ph.D. which was announced earlier. At the direction of Mr. Tardugno, the nominating committee of the board of directors has begun the process to identify qualified candidates to fill the vacancy on the company's board. Mr. Tardugno joined Celsion on January 3, 2007 as President and Chief Executive Officer and was elected to the Board of Directors on January 22, 2007.

Celsion Corporation Announces the Unexpected Passing of Max E. Link, Director and Chairman of Board of Directors

Celsion Corporation announced the passing of Max E. Link, a Director and the Chairman of the board of directors of the company. Dr. Link passed away unexpectedly at the age of 74.

Celsion Corp. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Celsion Corp. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLSN:US $2.54 USD 0.00

CLSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BSD Medical Corp $0.48 USD -0.06
Medifocus Inc C$0.08 CAD -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation CLSN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 89.0x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELSION CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at